Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy

International Journal of Gynecological Cancer

Volumn 21, Issue 5, 2011, Pages 822-830

  Aktas, Bahriye ^a   Kasimir Bauer, Sabine ^a   Heubner, Martin ^a   Kimmig, Rainer ^a   Wimberger, Pauline ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Circulating tumor cells; Disseminated tumor cells; Ovarian cancer; Platinum based chemotherapy

Indexed keywords

CA 125 ANTIGEN; CYTOKERATIN ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; MUCIN 1;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CIRCULATING TUMOR CELL; DISSEMINATED TUMOR CELL; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

EID: 80052795481     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318216cb91     Document Type: Article

References (45)

1. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16:viii7-viii12. (Pubitemid 41631227)
2. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115: 1234-1244.
3. Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: Current status and future directions. Semin Oncol. 2009;36:112-125.
4. Banys M, Solomayer EF, Becker S, et al. Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignancies. Int J Gynecol Cancer. 2009;19:948-952.
5. Schindlbeck C, Hantschmann P, Zerzer M, et al. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase II alpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Int J Gynecol Cancer. 2007;17:1047-1055. (Pubitemid 47414831)
6. Wimberger P, Heubner M, Otterbach F, et al. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol. 2007;107:331-338. (Pubitemid 47575736)
7. Wimberger P, Heubner M, Lindhofer H, et al. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Anticancer Res. 2009;29:1787-1791.
8. Kasimir-Bauer S. Circulating tumor cells as marker for risk assessment and treatment monitoring. Mol Diagn Ther. 2009;13:209-215.
9. Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods. 2010;50:289-297.
10. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14:7004-7010.
11. Ignatiadis M, Kallergi G, Ntoulia M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 2008;14:2593-2600.
12. Xenidis N, Ignatiadis M, Apostolaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009;27:2177-2184.
13. Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009;11:R59.
14. Tewes M, Aktas B, Welt A, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: An option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2009;115:581-590.
15. Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently expressed in metastatic breast cancer patients with circulating tumor cells. Breast Cancer Res. 2009;11:R46.
16. Theodoropoulos PA, Polioudaki H, Agelaki S, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010;288:99-106.
17. Kurata H, Takakuwa K, Tsuneki I, et al. Ovarian tumor cell detection in peripheral blood progenitor cells harvests by RT-PCR. Acta Obstet Gynecol Scand. 2002;81:555-559. (Pubitemid 34628086)
18. Marth C, Kisic J, Kaern J, et al. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer. 2002;94:707-712. (Pubitemid 34132299)
19. Sapi E, Okpokwasili NI, Rutherford T. Detection of telomerase-positive circulating epithelial cells in ovarian cancer patients. Cancer Detect Prev. 2002;26:158-167. (Pubitemid 36016914)
20. Judson PL, Geller MA, Bliss RL, et al. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol. 2003;91:389-394. (Pubitemid 37346335)
21. Oikonomopoulou K, Scorilas A, Michael IP, et al. Kallikreins as markers of disseminated tumour cells in ovarian cancer: A pilot study. Tumour Biol. 2006;27:104-114.
22. HeW, Kularatne SA, Kalli KR, et al. Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer. 2008;123:1968-1973.
23. Fan T, Zhao Q, Chen JJ, et al. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol. 2009;112:185-191.
24. Demel U, Tilz GP, Foeldes-Papp Z, et al. Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay. J Exp Clin Cancer Res. 2004;23:465-468. (Pubitemid 39490631)
25. Zieglschmid V, Hollmann C, Gutierrez B, et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res. 2005;25:1803-1810. (Pubitemid 40896806)
26. Lee KR, Jetal TFP. Surface Epithelial-Stromal Tumours. World Health Organization Classification of Tumours. Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:117-145.
27. Silverberg SG. Histopathologic grading of ovarian carcinoma: A review and proposal. Int J Gynecol Pathol. 2000;19:7-15. (Pubitemid 30010638)
28. FIGO. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105:3-4.
29. Fehm T, Braun S, Müller V, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow of patients with primary breast cancer and its clinical implementation. Cancer. 2006;197:885-892. (Pubitemid 44291136)
30. Borgen E, Naume B, Nesland JM, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells: The European ISHAGE Working Group for Standardization of Tumor Cell Detection. Cytotherapy. 1999;5:377-388.
31. Lankiewicz S, Rivero BG, Bócher O. Quantitative real-time RT-PCR of disseminated tumor cells in combination withimmunomagnetic cell enrichment. Mol Biotechnol. 2006;34:15-28.
32. Hauch S, Zimmermann S, Lankiewicz S, et al. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res. 2007;27: 1337-1341. (Pubitemid 46807280)
33. Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11:R46.
34. Wang L, Ma J, Liu FH, et al. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer an its therapeutic significance. Gynecol Oncol. 2007;105: 695-702. (Pubitemid 46734194)
35. Hoopmann M, Sachse K, Valter MM, et al. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. EUR J Cancer Care (Engl). 2010;19:809-815.
36. Schoppmeyer K, Fruhauf N, Oldhafer K, et al. Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases. Oncol Rep. 2006;15:449-454.
37. Rack B, Mü ller V, Kasimir-Bauer S, et al. Minimal residual cancer and its clinical relevance. Curr Breast Cancer Rep. 2009;1:198-206.
38. Mehes G, Witt A, Kubista E, et al. Circulating breast cancer cells are frequently apoptotic. Am J Pathol. 2001;159:17-20. (Pubitemid 33704186)
39. Parmar MK, Ledermann JA, Colombo N, et al. ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in woman with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-2106.
40. Balzar M, Winter MJ, de Boer CJ, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med. 1999;77:699-712.
41. Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM-anti-CD3 antibody: A phase I/II study. Clin Cancer Res. 2007;13:3899-3905. (Pubitemid 47037597)
42. Moreno M, Bontkes HJ, Scheper RJ, et al. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 2007;25:47-55. (Pubitemid 47464696)
43. Agrawal B, Gendler SJ, Longenecker BM. The biological role of mucins in cellular interactions and immune regulation: Prospects for cancer immunotherapy. Mol Med Today. 1998;4:397-403. (Pubitemid 28411034)
44. Chauhan SC, Vinayek N, Maher DM, et al. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: Antigens for multi-targeted antibody-guiede therapy. J Histochem Cytochem. 2007;55:867-875. (Pubitemid 47068277)
45. Pfisterer J, du Bois A, Sehouli J, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol. 2006;17: 1568-1577. (Pubitemid 44548850)